ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)
Year: 2018
Type: article
Institutions: University of Alabama at Birmingham, Hospital of Prato, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Complejo Hospitalario Universitario de Santiago, Brown University, Universidad Complutense de Madrid, Instituto de Salud Carlos III, Research Institute Hospital 12 de Octubre, Hospital Universitario 12 De Octubre, Red Espanola de Investigacion en Patologia Infecciosa, Instituto Maimónides de Investigación Biomédica de Córdoba, Hospital Universitario Reina Sofía, University of Córdoba
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: anti-TNF therapy, tuberculosis reactivation, latent tuberculosis infection screening, HBV reactivation, antiviral prophylaxis, opportunistic infections, fungal infection, bacterial infection, Pneumocystis prophylaxis, infliximab, adalimumab, golimumab, certolizumab pegol, etanercept, immunocompromised patients, infection control
Open Access status: bronze
OpenAlex ID: W2788644810
